Stock Info Nets

Independent Financial Information Made Easy

Our AI creates

The Best Stock Graphs and Charts

Youtube Subscribe Blog GamificArt

The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.

General Description

Intellia Therapeutics

Youtube Subscribe

...

Ticker: NTLA

Sector: Biotechnology

Intellia Therapeutics Inc. (NTLA) Director Muna Bhanji sold 1,867 shares of the company in a transaction on Thursday, July 6th. Director Munani Bhanj now holds 12.
...
...
Extended Summary

Intellia Therapeutics

Intellia Therapeutics Inc. (NTLA) Director Muna Bhanji sold 1,867 shares of the company in a transaction on Thursday, July 6th. Cyndeo Wealth Partners LLC acquired a new position in Intellya Therapeutic, Inc. in Stock. Intellia Therapeutics is anticipated to post earnings of ($4.05) per share for the year. This forecast comes amidst a consensus estimate of $5.33 per share. Director Muna Bhanji now holds 12,526 shares in the company valued at $492,271. Wall Street analysts think its a good time to buy Intellia Therapeutics stock. Out of 16 sell side analysts who give forecasts on NTLA, the consensus analyst rating is a Strong Buy. NTLA does not generate passive income. Cambridge, MA, is hiring associate director, clinical data management in cambridge, massachusetts, united states. Sandia Investment Management LP acquired a new position in shares of Intellia Therapeutics in the fourth quarter valued at approximately $35,000. CWM LLC boosted its holdings in shares by 2,072.7% in the first quarter. Raymond James & Associates owns 0.06% of Intellia Therapeutics worth $1,972,000 at the end of the most recent quarter. Director Muna Bhanji sold 1,867 shares of the businesss stock in a transaction on Thursday, July 6th.

Related Results

...
February 23, 2024 6:58 (London Time)

Intellia Therapeutics

Intellia Therapeutics (NTLA) posted Phase 1 study results of its NTLA-2002 for hereditary angioedema ( HAE ) in the New England Journal of Medicine.…
Sector: Biotechnology
Ticker: NTLA
Sentiment: 0.296
MarketCap: 2,434,101,937.0
High: 27.88 Low: 25.33

Open: 26.5 Close: 27.18 Change: 0.68

Read more →
...
December 14, 2023 4:25 (London Time)

Intellia Therapeutics

Caribou Biosciences shares currently trade for just below $6. Caribou has potential to multiply in value.
Sector: Biotechnology
Ticker: NTLA
Sentiment: 0.7269
MarketCap: 2,720,677,588.0
High: 30.45 Low: 26.94

Open: 27.91 Close: 30.39 Change: 2.48

Read more →
...
August 29, 2023 14:10 (London Time)

Intellia Therapeutics

Intellia Therapeutics, Inc. (NTLA) has the potential to rally 185.4% as Wall Street Analysts expect? Wall Street expects the companys stock to rise …
Sector: Biotechnology
Ticker: NTLA
Sentiment: 0.9524
MarketCap: 3,363,541,009.0
High: 38.22 Low: 37.52

Open: 38.0 Close: 38.04 Change: 0.04

Read more →
...
February 05, 2024 16:28 (London Time)

Intellia Therapeutics

Intellia Therapeutics stock is falling after falling after the company announced a public offering on Thursday. NTLA stock jumped on the implication…
Sector: Biotechnology
Ticker: NTLA
Sentiment: -0.2263
MarketCap: 2,264,843,193.0
High: 25.06 Low: 24.23

Open: 24.81 Close: 24.59 Change: -0.22

Read more →
...
September 10, 2023 0:51 (London Time)

Intellia Therapeutics

Intellia Therapeutics Inc. (NTLA) Average Target Price: $82.70 Potential Upside: 117.8%. Average target price: $83.70 - potential upside: $81.70. In…
Sector: Biotechnology
Ticker: NTLA
Sentiment: 0.0
MarketCap: 3,351,152,276.0
High: 37.97 Low: 37.02

Open: 37.87 Close: 37.87 Change: 0.0

Read more →
...
July 20, 2023 15:01 (London Time)

Intellia Therapeutics

Director Muna Bhanji sold 1,867 shares of the company in a transaction on Thursday, July 6th. NTLA does not generate passive income.
Sector: Biotechnology
Ticker: NTLA
Sentiment: 0.9851
MarketCap: 4,020,991,416.0
High: 45.38 Low: 43.32

Open: 44.97 Close: 43.64 Change: -1.33

Read more →
Search
Happening Now
Categories